Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

FATE
Fate Therapeutics, Inc.
stock NASDAQ

At Close
Jul 30, 2026 3:59:59 PM EDT
2.52USD+6.568%(+0.16)989,004
2.51Bid   2.52Ask   0.01Spread
Pre-market
Jul 30, 2026 9:23:30 AM EDT
2.32USD-1.669%(-0.04)8,450
After-hours
Jul 29, 2026 4:02:30 PM EDT
2.37USD+0.424%(+0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:04AM EST  Fate Therapeutics Announces FDA Clearance For FT536, A First-in-class MICA/B-Targeted CAR NK Cell Product Candidate For Treatment Of Solid Tumors   Benzinga
08:00AM EST  Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB   GlobeNewswire Inc
Jan 5, 2022
11:04AM EST  Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today   Benzinga
Dec 15, 2021
04:19PM EST  16:19 Wednesday, December 15, 2021Wedbush (RTTNews) - Wedbush Ups Fate Therapeutics, Inc (FATE) To Outperform From Neutral With $74 Up From $71 Price Target   RTTNews
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021   Benzinga
09:23AM EST  Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $62   Benzinga
07:26AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
07:07AM EST  Wedbush Upgrades Fate Therapeutics to Outperform, Raises Price Target to $74   Benzinga
06:42AM EST  HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $122   Benzinga
Dec 14, 2021
08:22AM EST  The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks   Benzinga
Dec 13, 2021
04:32PM EST  UPDATE: Fate Therapeutics Says 5 Of 6 Patients Achieved Objective Response 'including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab'   Benzinga
04:32PM EST  Fate Therapeutics Showcases Interim Phase 1 Data From FT596 Off-The-Shelf, iPSC-Derived CAR NK Cell Program For Relapsed / Refractory B-cell Lymphoma At ASH 2021 Meeting   Benzinga
04:31PM EST  5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab   GlobeNewswire Inc
09:26AM EST  Fate Therapeutics Announces FDA Has Granted Regenerative Medicine Advanced Therapy Designation To FT516   Benzinga
09:25AM EST  Fate Therapeutics Highlights Presentation Of Durability of Response Data From FT516 Phase 1 Study For B-cell Lymphoma At ASH Meeting   Benzinga
09:01AM EST  6 of 10 Patients Nave to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at 90 Million FT516 Cells per Dose   GlobeNewswire Inc
Dec 8, 2021
05:45PM EST  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled B -cell Lymphoma Franchise Update on Tuesday,December 14, 2021 at 8:00 AM ET.   GlobeNewswire Inc
Dec 7, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021   Benzinga
08:40AM EST  Cowen & Co. Initiates Coverage On Fate Therapeutics with Outperform Rating   Benzinga
Nov 11, 2021
08:00AM EST  Fate Therapeutics, Inc. (the Company or Fate Therapeutics) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:   GlobeNewswire Inc
Nov 9, 2021
12:02PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021   Benzinga
11:54AM EST  Fate Therapeutics Highlights Abstract On FT538, FT573 Programs Were Selected For Presentation at Society For Immunotherapy Of Cancer Meeting Nov. 10 12:30-2 p.m. EST   Benzinga
11:31AM EST  Citigroup Upgrades Fate Therapeutics to Buy, Lowers Price Target to $87   Benzinga
09:00AM EST  Fate Therapeutics Announces Abstract Highlighting FT538 and FT573   GlobeNewswire Inc
Nov 8, 2021
11:37AM EST  UPDATE: SVB Leerink On Fate Price Target Trim: Sees Induced Pluripotent Stem Cell (iPSC)-Derived Cell Candidates FT596 & FT516 To Present At The American Society For Hematology On 12/13; Notes Increased Cash Burn With Est. At $210M In FY21 & $306M In FY22   Benzinga
06:34AM EST  SVB Leerink Maintains Outperform on Fate Therapeutics, Lowers Price Target to $115   Benzinga
Nov 5, 2021
09:22AM EDT  Fate Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate, Sales $14.22M Beat $7.89M Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 25, 2021
08:00AM EDT  Fate Therapeutics to Webcast Conference Call Reporting Third   GlobeNewswire Inc
Oct 12, 2021
11:08AM EDT  3 Biotech Stocks to Watch Now   Benzinga
Oct 6, 2021
09:51AM EDT  Fate Therapeutics Sponsored Study Titled 'FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting   Benzinga
Oct 1, 2021
08:01AM EDT  Fate Therapeutics Announces Presentations at the Society for   GlobeNewswire Inc
Sep 15, 2021
08:05AM EDT  Fate Therapeutics Announces Publication Of FT538 Preclinical Data Demonstrating Enhanced Serial Killing And Functional Persistence Without Cytokine Support   Benzinga
08:00AM EDT  Fate Therapeutics Announces Publication of FT538 Preclinical Data   GlobeNewswire Inc
Sep 2, 2021
04:01PM EDT  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:   GlobeNewswire Inc
Aug 26, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021   Benzinga
07:58AM EDT  Morgan Stanley Initiates Coverage On Fate Therapeutics with Equal-Weight Rating, Announces Price Target of $77   Benzinga
Aug 20, 2021
10:15AM EDT  Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations   Benzinga
08:47AM EDT  Fate Therapeutics shares are trading lower after the company announced interim data from its FT596 and FT516 programs for patients with relapsed / refractory B-cell lymphoma.   Benzinga
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
04:02PM EDT  Fate Therapeutics Announces Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma   Benzinga
04:01PM EDT  10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy   GlobeNewswire Inc
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 16, 2021
08:57AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Aug. 16, 2021: MGI, ENLV, GNUS, PCG, FATE   Benzinga
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 5, 2021
06:57AM EDT  SVB Leerink Maintains Outperform on Fate Therapeutics, Lowers Price Target to $118   Benzinga
06:51AM EDT  HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $121   Benzinga
Aug 4, 2021
04:41PM EDT  Fate Therapeutics Q2 EPS $(0.58) Misses $(0.53) Estimate, Sales $13.41M Up From $5.46M YoY   Benzinga
04:01PM EDT  First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus   GlobeNewswire Inc
08:00AM EDT  Fate Therapeutics Appoints Yuan Xu to its Board of Directors   GlobeNewswire Inc
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Aug 2, 2021
04:51PM EDT  Fate Therapeutics Reports Treatment Of First Patient In Phase 1 Trial Of FT819   Benzinga
04:50PM EDT  Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 16, 2021
08:04AM EDT  Fate Therapeutics Highlights Will Host Virtual Event On Interim Phase 1 Trial Data From Its Off-The-Shelf NK Cell Franchise For B-Cell Lymphoma   Benzinga
08:00AM EDT  Fate Therapeutics to Host Virtual Event Highlighting Interim Phase   GlobeNewswire Inc
Jul 15, 2021
04:02PM EDT  Fate Therapeutics, Inc.(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast onWednesday, August 4, 2021at5:00 p.m. ETto report its second quarter 2021 financial results and provide a corporate update.   GlobeNewswire Inc
Jun 15, 2021
08:00AM EDT  Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief   GlobeNewswire Inc
Jun 7, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021   Benzinga
06:19AM EDT  HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Announces $120 Price Target   Benzinga
Jun 4, 2021
03:06PM EDT  Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21   Benzinga
07:14AM EDT  Fate Therapeutics Highlights Positive Interim Data From FT516 Phase 1 Study With Rituximab For B-cell Lymphoma At ASCO   RTTNews
07:03AM EDT  Fate Therapeutics Reports Interim Data From Phase 1 Study Of FT516 In Combo With Rituximab For B-Cell Lymphoma At American Society Of Clinical Oncology   Benzinga
07:00AM EDT  8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response   GlobeNewswire Inc
May 25, 2021
04:01PM EDT  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:   GlobeNewswire Inc
May 14, 2021
08:17AM EDT  Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients   Benzinga
May 13, 2021
04:31PM EDT  Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia   Benzinga
04:01PM EDT  4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 5, 2021
04:20PM EDT  Fate Therapeutics Q1 EPS $(0.48) Misses $(0.43) Estimate, Sales $11.14M Beat $5.90M Estimate   Benzinga
04:01PM EDT  IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021   GlobeNewswire Inc
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:28AM EDT  Preview: Fate Therapeutics's Earnings   Benzinga
Apr 29, 2021
08:00AM EDT  Fate Therapeutics to Webcast Conference Call Reporting First   GlobeNewswire Inc
Mar 30, 2021
12:04AM EDT  Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday   Benzinga
Mar 25, 2021
07:00AM EDT  Fate Therapeutics Announces Retirement of Chief Scientific Officer   GlobeNewswire Inc
Mar 12, 2021
08:24AM EST  10 Biggest Price Target Changes For Friday   Benzinga
06:28AM EST  SVB Leerink Maintains Outperform on Fate Therapeutics, Raises Price Target to $121   Benzinga
Mar 8, 2021
07:00AM EST  Fate Therapeutics, Inc. (the Company or Fate Therapeutics)(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:   GlobeNewswire Inc
Mar 4, 2021
10:46AM EST  Wells Fargo Maintains Overweight on Fate Therapeutics, Raises Price Target to $130   Benzinga
Feb 26, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021   Benzinga
07:36AM EST  Wedbush Downgrades Fate Therapeutics to Neutral   Benzinga
Feb 25, 2021
11:50AM EST  Cantor Fitzgerald Maintains Overweight on Fate Therapeutics, Raises Price Target to $98   Benzinga
11:17AM EST  Mizuho Maintains Buy on Fate Therapeutics, Raises Price Target to $109   Benzinga
Feb 24, 2021
04:55PM EST  Fate Therapeutics: Q4 Earnings Insights   Benzinga
04:05PM EST  Fate Therapeutics Q4 EPS $(0.61) Misses $(0.39) Estimate, Sales $15.90M May Not Compare To $4.87M Estimate   Benzinga
04:01PM EST  Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3   GlobeNewswire Inc
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 22, 2021
04:01PM EST  Fate Therapeutics, Inc. (the Company or Fate Therapeutics)(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the upcoming 10thAnnual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 5:00 p.m. EST.   GlobeNewswire Inc
Feb 19, 2021
08:00AM EST  Fate Therapeutics to Webcast Conference Call Reporting Fourth   GlobeNewswire Inc
Feb 17, 2021
07:02PM EST  Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Feb. 17, 2021: ABBV, VEEV, SGFY, EXAS, CMLF, BFLY, TSLA, SHOP, NTDOY, IRDM, FATE, BEAM, TDY, RAVN, KMTUY   Benzinga
10:58AM EST  Piper Sandler Maintains Overweight on Fate Therapeutics, Raises Price Target to $116   Benzinga
Jan 28, 2021
07:28PM EST  CORRECTION: Cathie Wood's ARK Invests' Stock Purchases For Thursday, Jan. 28, 2021: RPTX, ACCD, CDXS, IONS, NVS, FATE, TSLA, EXPC, TER, SKLZ   Benzinga
Jan 27, 2021
06:46AM EST  HC Wainwright & Co. Assumes Fate Therapeutics at Neutral, Announces Price Target of $108   Benzinga
Jan 16, 2021
02:22PM EST  Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 8, 2021
04:26PM EST  Fate Therapeutics Announces Completion of Public Offering of   GlobeNewswire Inc
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 6, 2021
05:32AM EST  Fate Therapeutics Priced 4.4M Share Public Offering of Common Stock @$85.50/Share   Benzinga
12:30AM EST  Fate Therapeutics Announces Pricing of Public Offering of Common   GlobeNewswire Inc
Jan 5, 2021
10:40AM EST  Fate Therapeutics shares were trading lower after the company announced a proposed offering of $350 million of stock.   Benzinga
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Jan 4, 2021
04:02PM EST  Fate Therapeutics Announces Proposed Offering Of $350M Of Stock   Benzinga
04:02PM EST  Fate Therapeutics Announces Proposed Public Offering Of $350M Of Common Stock   Benzinga
04:01PM EST  Fate Therapeutics Announces Proposed Public Offering of $350   GlobeNewswire Inc
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
08:06AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:59AM EST  SVB Leerink Maintains Outperform on Fate Therapeutics, Raises Price Target to $58   Benzinga
Dec 6, 2020
10:05AM EST  Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells   GlobeNewswire Inc
Dec 4, 2020
04:01PM EST  3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response   GlobeNewswire Inc
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 30, 2020
08:00AM EST  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled The Power of hnCD16 on Friday,December 4, 2020 at 4:30 PM EDT.   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 12, 2020
04:01PM EST  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:   GlobeNewswire Inc
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 6, 2020
08:14AM EST  BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $43   Benzinga
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
04:33PM EST  Fate Therapeutics Q3 EPS $(0.68) Misses $(0.36) Estimate, Sales $7.56M Beat $6.97M Estimate   Benzinga
08:09AM EST  Fate Therapeutics Announces Twelve Presentations At The 2020 ASH Annual Meeting Dec. 5-7   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
07:00AM EST  Fate Therapeutics to Webcast Conference Call Reporting Third   GlobeNewswire Inc
Oct 15, 2020
08:00AM EDT  FateTherapeutics Announces Presentations at the 2020   GlobeNewswire Inc
Sep 30, 2020
08:01AM EDT  FateTherapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Tuesday, October 6, 2020 and 2:30 p.m. E.T.   GlobeNewswire Inc
Sep 4, 2020
08:00AM EDT  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 19, 2020
08:07AM EDT  Fate Therapeutics Appoints Edward Dulac As Chief Financial Officer   Benzinga
Aug 13, 2020
09:33AM EDT  Cantor Fitzgerald Maintains Overweight on Fate Therapeutics, Raises Price Target to $40   Benzinga
Aug 12, 2020
01:47PM EDT  Shares Of Fate Therapeutics Move Higher; Traders Circulate The Stem Cellar Post Highlighting Success Of Co.'s FT516 In Coronavirus Trial   Benzinga
Aug 5, 2020
04:04PM EDT  Fate Therapeutics Q2 EPS $(0.35) Misses $(0.27) Estimate, Sales $5.37M Miss $13.23M Estimate   Benzinga
04:01PM EDT  Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Aug 4, 2020
04:01PM EDT  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020, at 11:30 a.m. EST.   GlobeNewswire Inc
Jul 29, 2020
04:01PM EDT  Fate Therapeutics to Webcast Conference Call Reporting Second   GlobeNewswire Inc
Jul 14, 2020
08:08AM EDT  Fate Therapeutics Announces Exclusive License Agreement With Baylor College Of Medicine For Rejection-Resistant iPSC-Derived Cellular Therapies   Benzinga
08:00AM EDT  License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC